D M Harper

Summary

Affiliation: Dartmouth Medical School
Country: USA

Publications

  1. ncbi Factors affecting the detection rate of human papillomavirus
    Diane M Harper
    Department of Obstetrics and Gynecology, Dartmouth Medical School, Hanover, NH, USA
    Ann Fam Med 1:221-7. 2003
  2. ncbi Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age
    Diane M Harper
    Department of Obstetrics and Gynecology, Dartmouth Medical School, Hanover, NH, USA
    Gynecol Oncol 110:S11-7. 2008
  3. ncbi Age for HPV vaccination
    Diane M Harper
    Dartmouth College, Department of Women s and Gender Studies, Obstetrics and Gynecology, Community and Family Medicine, Hanover, NH, USA
    Vaccine 26:A7-11. 2008
  4. ncbi Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
    Diane M Harper
    Department of Obstetrics and Gynecology, Norris Cotton Cancer Center, Dartmouth Medical School, Rubin 880, One Medical Center Drive, Lebanon, NH 03756, USA
    Lancet 367:1247-55. 2006
  5. ncbi Self-reported desire to improve colposcopic impressions
    D M Harper
    Department of Obstetrics and Gynecology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Arch Gynecol Obstet 264:137-42. 2000
  6. ncbi Healing experiences after cervical cryosurgery
    D M Harper
    Department of Community and Family Medicine, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA
    J Fam Pract 49:701-6. 2000
  7. ncbi The natural history of cervical cryosurgical healing. The minimal effect of debridement of the cervical eschar [see comment]
    D M Harper
    Department of Community and Family Medicine, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA
    J Fam Pract 49:694-700. 2000
  8. ncbi Collection devices for human papillomavirus
    D M Harper
    Dartmouth Medical School, Norris Cotton Cancer Center, Hanover, New Hampshire, USA
    J Fam Pract 48:531-5. 1999
  9. ncbi Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
    Diane M Harper
    Department of Obstetrics and Gynecology, Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH, USA
    Lancet 364:1757-65. 2004
  10. ncbi The technical performance and clinical feasibility of telecolposcopy
    D M Harper
    Department of Obstetrics and Gynecology, Dartmouth Medical School, Hanover, New Hampshire, USA
    J Fam Pract 49:623-7. 2000

Detail Information

Publications38

  1. ncbi Factors affecting the detection rate of human papillomavirus
    Diane M Harper
    Department of Obstetrics and Gynecology, Dartmouth Medical School, Hanover, NH, USA
    Ann Fam Med 1:221-7. 2003
    ..The purpose of this study was to determine whether cyclic hormonal variation, recent sexual intercourse, interval between samplings, and the technique used to sample affect the detection of HPV...
  2. ncbi Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age
    Diane M Harper
    Department of Obstetrics and Gynecology, Dartmouth Medical School, Hanover, NH, USA
    Gynecol Oncol 110:S11-7. 2008
    ..As this vaccine is used over time in universal prophylactic HPV-16/18 vaccination of girls and women, reductions in cervical cancers at both the individual and public health levels will be appreciated...
  3. ncbi Age for HPV vaccination
    Diane M Harper
    Dartmouth College, Department of Women s and Gender Studies, Obstetrics and Gynecology, Community and Family Medicine, Hanover, NH, USA
    Vaccine 26:A7-11. 2008
    ..The need for booster shots must therefore be addressed with patients as unknown. Continued cervical cancer screening is necessary regardless of vaccination. Vaccination alone will not eliminate cervical cancer...
  4. ncbi Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
    Diane M Harper
    Department of Obstetrics and Gynecology, Norris Cotton Cancer Center, Dartmouth Medical School, Rubin 880, One Medical Center Drive, Lebanon, NH 03756, USA
    Lancet 367:1247-55. 2006
    ....
  5. ncbi Self-reported desire to improve colposcopic impressions
    D M Harper
    Department of Obstetrics and Gynecology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Arch Gynecol Obstet 264:137-42. 2000
    ....
  6. ncbi Healing experiences after cervical cryosurgery
    D M Harper
    Department of Community and Family Medicine, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA
    J Fam Pract 49:701-6. 2000
    ..The subsequent healing process is also thought to bring discomfort. The purpose of our study was to describe women's experiences after cryosurgery, and how obesity, age, and gravidity affected, the healing process...
  7. ncbi The natural history of cervical cryosurgical healing. The minimal effect of debridement of the cervical eschar [see comment]
    D M Harper
    Department of Community and Family Medicine, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA
    J Fam Pract 49:694-700. 2000
    ..A secondary purpose was to determine the effect of mechanical debridement of the cervical eschar on the symptoms of healing...
  8. ncbi Collection devices for human papillomavirus
    D M Harper
    Dartmouth Medical School, Norris Cotton Cancer Center, Hanover, New Hampshire, USA
    J Fam Pract 48:531-5. 1999
    ..The purpose of this study is to determine whether a self-collection device for cervicovaginal HPV infection could be developed...
  9. ncbi Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
    Diane M Harper
    Department of Obstetrics and Gynecology, Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH, USA
    Lancet 364:1757-65. 2004
    ....
  10. ncbi The technical performance and clinical feasibility of telecolposcopy
    D M Harper
    Department of Obstetrics and Gynecology, Dartmouth Medical School, Hanover, New Hampshire, USA
    J Fam Pract 49:623-7. 2000
    ....
  11. ncbi Cervical mucosal block effectively reduces the pain and cramping from cryosurgery
    D M Harper
    Department of Obstetrics and Gynecology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    J Fam Pract 47:285-9. 1998
    ..The purpose of our study was to determine how effective a four-quadrant cervical mucosal block is in reducing the pain and cramping of cryosurgery...
  12. ncbi Tampon samplings with longer cervicovaginal cell exposures are equivalent to two consecutive swabs for the detection of high-risk human papillomavirus
    Diane M Harper
    Department of Obstetrics and Gynecology, Dartmouth Medical School, Hanover, New Hampshire, USA
    Sex Transm Dis 29:628-36. 2002
    ..Self-sampling for human papillomavirus (HPV) is useful for triage of ASCUS Papanicolaou (Pap) smears. Tampons with 10-second cervicovaginal cell exposure can detect HPV but appear to be less efficient than two consecutive swabs...
  13. ncbi Is it cost-effective to use a mucosal or paracervical block to relieve the pain and cramping from cryosurgery? A decision model
    D M Harper
    Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, NH, USA
    J Fam Pract 48:285-90. 1999
    ..The purpose of this article is to recommend the use of mucosal block, paracervical block, or no block on the basis of which procedure minimizes the costs of averting the pain and cramping that a woman experiences during cryosurgery...
  14. ncbi Are we closer to the prevention of HPV-related diseases?
    Diane M Harper
    Gynecologic Cancer Prevention Research Group, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH USA
    J Fam Pract . 2005
  15. ncbi Analysis of acetic acid-induced whitening of high-grade squamous intraepithelial lesions
    B W Pogue
    Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA
    J Biomed Opt 6:397-403. 2001
    ..This imaging and data normalization procedure may be applied to cervical lesions of different grades, to determine if a quantitative estimate provides predictive value during the colposcopic diagnosis...
  16. ncbi Does comprehensive preventive medicine training enhance clinical prevention?
    N B Comninellis
    Department of Community and Family Medicine, University of Missouri Kansas City, USA
    Fam Med 29:112-4. 1997
    ....
  17. ncbi Current prophylactic HPV vaccines and gynecologic premalignancies
    Diane M Harper
    Department of Community and Family Medicine, University of Missouri Kansas City School of Medicine, Truman Medical Center Lakewood, Kansas City, Missouri 64139, USA
    Curr Opin Obstet Gynecol 21:457-64. 2009
    ..Safety reports indicate injection site reactions for both Cervarix and Gardasil. Rare serious adverse events have been reported...
  18. ncbi Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed--biologic concordance and women's preferences
    Diane M Harper
    Department of Obstetrics and Gynecology, Dartmouth Medical School, Hannover, NH, USA
    Am J Obstet Gynecol 186:365-73. 2002
    ..The purpose of this study was to compare the high-risk human papillomavirus detection rates from self-sampled swabs and tampons with standard clinician-directed speculum sampling and to assess women's acceptance of self-sampling methods...
  19. ncbi Leukocytes in the cervix: a quantitative evaluation of cervicitis
    J E Stern
    Department of Obstetrics and Gynecology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03755, USA
    Obstet Gynecol 91:987-92. 1998
    ..To quantify the numbers of leukocytes in the normal cervix and relate these numbers to the diagnosis of cervicitis...
  20. ncbi Currently approved prophylactic HPV vaccines
    Diane M Harper
    Department of Community and Family Medicine, University of Missouri Kansas City School of Medicine, 7900 Lee s Summit Road, Kansas City, MO 64139, USA
    Expert Rev Vaccines 8:1663-79. 2009
    ..The most important determinant of vaccine impact to reduce cervical cancer is its duration of efficacy. To date, Cervarix's efficacy is proven for 6.4 years and Gardasil's for 5 years...
  21. ncbi Cervico-isthmic corporeal pregnancy with delivery at term: a review of the literature with a case report
    Daniel M Avery
    Department of Obstetrics and Gynecology, University of Alabama, University Medical Center, Tuscaloosa, Alabama 35401, USA
    Obstet Gynecol Surv 64:335-44. 2009
    ..However, cervico-isthmic and cervico-isthmic corporeal pregnancies are more likely to persist to an advanced gestation in the second and third trimester and cause profuse bleeding with attempted removal of the placenta...
  22. ncbi Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
    Luisa L Villa
    Department of Virology, Ludwig Institute for Cancer Research, Sao Paulo, Brazil
    Lancet Oncol 6:271-8. 2005
    ....
  23. ncbi Why am I scared of HPV?
    Diane M Harper
    CA Cancer J Clin 54:245-7. 2004
  24. ncbi Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
    Jorma Paavonen
    University of Helsinki, Department of Obstetrics and Gynaecology, Helsinki, Finland
    Lancet 369:2161-70. 2007
    ....
  25. ncbi Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
    Elmar A Joura
    Department of Gynecology and Obstetrics, Medical University of Vienna, Vienna, Austria
    Lancet 369:1693-702. 2007
    ..Our aim was to do a combined analysis of three randomised clinical trials to assess the effect of a prophylactic quadrivalent HPV vaccine on the incidence of these diseases...
  26. ncbi Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines
    Suzanne M Garland
    Microbiology and Infectious Diseases Department, Royal Women s Hospital, Carlton, University of Melbourne, Melbourne, Victoria, Australia
    Clin Vaccine Immunol 14:792-5. 2007
    ....
  27. ncbi Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control
    Eduardo L Franco
    Division of Cancer Epidemiology, Department of Oncology and Epidemiology, McGill University, 546 Pine Avenue West, Montreal, Que, Canada H2W 1S6
    Vaccine 23:2388-94. 2005
    ..It will take many years before we can rationally develop cervical cancer screening strategies that will be cost-effective for the proper surveillance of women protected by HPV vaccination...
  28. ncbi Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
    Luisa L Villa
    Department of Virology, Ludwig Institute for Cancer Research, R Prof Antonio Prudente 109, 4th Floor, 01509 010 Sao Paulo, SP, Brazil
    Vaccine 24:5571-83. 2006
    ..Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported...
  29. ncbi American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors
    Debbie Saslow
    Cancer Control Science Department, American Cancer Society, Altanta, GA, USA
    CA Cancer J Clin 57:7-28. 2007
    ..They address the use of prophylactic HPV vaccines, including who should be vaccinated and at what age, as well as a summary of policy and implementation issues. Implications for screening are also discussed...
  30. ncbi Interpretation of colposcopy data
    Diane M Harper
    J Fam Pract 52:390, 392; author reply 392. 2003
  31. ncbi Optical detection of high-grade cervical intraepithelial neoplasia in vivo: results of a 604-patient study
    Warner K Huh
    University of Alabama at Birmingham, Birmingham, Alabama 35233 7333, USA
    Am J Obstet Gynecol 190:1249-57. 2004
    ..The purpose of this study was to assess the in vivo optical detection of high-grade cervical intraepithelial neoplasia (2/3+) on the whole cervix with a noncontact, spectroscopic device...
  32. ncbi Beyond the Pap: assessing patients' priorities for the annual examination
    Heidi I Becker
    Texas Tech University Health Sciences Center, El Paso, Texas, USA
    J Womens Health (Larchmt) 13:791-8. 2004
    ....
  33. ncbi Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]: profile report
    Susan J Keam
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 22:205-8. 2008
  34. ncbi Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]
    Susan J Keam
    Wolters Kluwer Health Adis, Auckland, New Zealand demail adis co nz
    Drugs 68:359-72. 2008
    ..The HPV 16/18 vaccine was generally well tolerated and injection-site reactions were the most common vaccine-related adverse events reported...
  35. ncbi Toward optimal health: Diane M. Harper, M.D., M.S., M.P.H., discusses the HPV vaccine and the prevention of cervical cancer. Interview by Jodi R. Godfrey
    Diane M Harper
    J Womens Health (Larchmt) 16:1397-1401. 2007
  36. ncbi Chapter 13: Current findings from prophylactic HPV vaccine trials
    Laura A Koutsky
    Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA 98195, USA
    Vaccine 24:S3/114-21. 2006
    ..Both vaccines have the potential to substantially reduce HPV-related morbidity and mortality. This review focuses on published data from clinical trials of these two vaccines...
  37. ncbi Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
    Suzanne M Garland
    Microbiology and Infectious Diseases Department, Royal Women s Hospital, and the University of Melbourne, Melbourne, Australia
    N Engl J Med 356:1928-43. 2007
    ..A phase 3 trial was conducted to evaluate the efficacy of a prophylactic quadrivalent vaccine in preventing anogenital diseases associated with human papillomavirus (HPV) types 6, 11, 16, and 18...
  38. ncbi How condom use, number of receptive anal intercourse partners and history of external genital warts predict risk for external anal warts
    D J Wiley
    Division of Primary Care, School of Nursing, UCLA, Los Angeles, CA 90095 6919, USA
    Int J STD AIDS 16:203-11. 2005
    ....